IRIS
BEZZIO, Cristina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.468
AS - Asia 1.348
EU - Europa 367
SA - Sud America 229
Continente sconosciuto - Info sul continente non disponibili 135
AF - Africa 32
OC - Oceania 2
Totale 3.581
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.395
SG - Singapore 786
CN - Cina 255
BR - Brasile 181
IT - Italia 178
VN - Vietnam 124
HK - Hong Kong 55
CA - Canada 39
DE - Germania 36
IN - India 33
FR - Francia 32
BD - Bangladesh 24
MX - Messico 21
GB - Regno Unito 20
FI - Finlandia 16
AR - Argentina 14
IE - Irlanda 14
NL - Olanda 14
EC - Ecuador 12
RU - Federazione Russa 12
ES - Italia 9
ZA - Sudafrica 9
PK - Pakistan 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
CO - Colombia 6
JP - Giappone 6
LT - Lituania 6
TR - Turchia 6
HN - Honduras 5
IQ - Iraq 5
JO - Giordania 5
NP - Nepal 5
PE - Perù 5
PL - Polonia 5
TN - Tunisia 5
ID - Indonesia 4
MA - Marocco 4
NG - Nigeria 4
PY - Paraguay 4
SA - Arabia Saudita 4
CL - Cile 3
CZ - Repubblica Ceca 3
IL - Israele 3
IR - Iran 3
KE - Kenya 3
LV - Lettonia 3
PS - Palestinian Territory 3
UZ - Uzbekistan 3
BE - Belgio 2
CH - Svizzera 2
CI - Costa d'Avorio 2
EG - Egitto 2
JM - Giamaica 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MY - Malesia 2
SE - Svezia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
VE - Venezuela 2
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
KH - Cambogia 1
LU - Lussemburgo 1
ML - Mali 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
TV - Tuvalu 1
UY - Uruguay 1
Totale 3.446
Salva come PNG Salva come JPEG
Città #
Singapore 336
Ashburn 214
San Jose 183
Council Bluffs 143
The Dalles 108
Milan 74
Beijing 67
Shanghai 67
Santa Clara 61
Chandler 57
Hong Kong 50
Dallas 48
Los Angeles 48
Ho Chi Minh City 40
New York 32
Rome 31
Hanoi 30
Buffalo 27
Boardman 23
Princeton 16
Helsinki 15
Dublin 14
Mexico City 14
Montreal 14
São Paulo 14
Phoenix 11
Lawrence 10
London 10
Seattle 10
Figino 9
Orem 9
Secaucus 9
Amsterdam 8
Brooklyn 8
Chennai 8
Düsseldorf 8
Wilmington 8
Da Nang 7
Frankfurt am Main 7
Atlanta 6
Houston 6
Quito 6
San Francisco 6
Toronto 6
Amman 5
Rio de Janeiro 5
Albany 4
Benin City 4
Charlotte 4
Chicago 4
Curitiba 4
Dubai 4
Johannesburg 4
Mumbai 4
Munich 4
Paris 4
Porto Alegre 4
Portsmouth 4
Raleigh 4
San Mateo 4
Tokyo 4
Warsaw 4
Belo Horizonte 3
Brasília 3
Chandigarh 3
Concord 3
Dhaka 3
Guayaquil 3
Irsina 3
Jacksonville 3
Las Vegas 3
Lima 3
Limeira 3
Madrid 3
Milwaukee 3
Nairobi 3
Naples 3
New Haven 3
Ninh Bình 3
Ottawa 3
Pune 3
São Bernardo do Campo 3
Taiyuan 3
Tashkent 3
Tegucigalpa 3
Thái Bình 3
Valencia 3
Abidjan 2
Alabaster 2
Ann Arbor 2
Asunción 2
Baltimore 2
Bishkek 2
Bologna 2
Bossier City 2
Boston 2
Bruino 2
Brussels 2
Cagliari 2
Campinas 2
Totale 2.053
Salva come PNG Salva come JPEG
Nome #
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 101
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy 91
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 89
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study 76
The learning curve for using intestinal ultrasonography 73
Dietary Fiber in Inflammatory Bowel Disease: Are We Ready to Change the Paradigm? 70
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 69
Factors correlated with transmural healing in patients with Crohn's disease in long-term clinical remission on anti-TNF medication 66
Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study 65
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 64
Efficacy of a novel self-assembling peptide hemostatic gel as rescue therapy for refractory acute gastrointestinal bleeding 61
Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons 59
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study 57
Prevalence and Clinical Impact of Immune-Mediated Inflammatory Diseases in Patients with Inflammatory Bowel Disease: Results from a Large Retrospective Observational Study 55
Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease 55
The Impact of Ustekinumab Biosimilar on Therapeutic Strategies in Crohn's Disease: A Paradigm Shift? 55
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease 53
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 53
Reporting of Magnetic Resonance Enterography in Inflammatory Bowel Disease: Results of an Italian Survey 53
Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease – A comprehensive narrative review 52
Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections 51
Hold the Foam : Why Topical Budesonide Remains Relevant for IBD Therapy 51
Nutritional care at centres managing patients with inflammatory bowel disease: A nationwide survey in Italy 50
Impact of histologic disease activity on long-term outcomes in patients with ileal pouch-anal anastomosis for ulcerative colitis 50
The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus 50
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy 49
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study 49
Biologic Therapies May Reduce the Risk of COVID-19 in Patients With Inflammatory Bowel Disease 49
Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It 48
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey 48
Ultrasonography Tight Control and Monitoring in Crohn’s Disease During Different Biological Therapies: A Multicenter Study 46
Unmet needs of Italian physicians managing patients with inflammatory bowel disease 46
Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review 46
Noninvasive Assessment of Postoperative Disease Recurrence in Crohn’s Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease 46
Efficacy, safety and tolerability, the imperfect triangle arising from the new low volume colon preparations 45
Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms in Northern Italy: A Single-Center Cohort Study 45
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study 44
Planning phase two for endoscopic units in Northern Italy after the COVID-19 lockdown: An exit strategy with a lot of critical issues and a few opportunities 43
IBD Flare in the COVID-19 Pandemic:Therapy Discontinuation Is to Blame 42
Endoscopic ultrasound-guided gallbladder drainage in pancreatic cancer and cholangitis: A case report 42
Neuroendocrine tumors in patients with inflammatory bowel disease: a case series 42
Management of proctitis in ulcerative colitis and the place of biological therapies 42
Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study 42
Prevalence, Risk Factors and Association with Clinical Outcomes of Malnutrition and Sarcopenia in Inflammatory Bowel Disease: A Prospective Study 42
Gastrointestinal ultrasound in inflammatory bowel disease: Seeing beyond limits 40
Does ProCore fine needle biopsy really improve the clinical outcome of endoscopic ultrasound-guided sampling of pancreatic masses? 39
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 39
Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology 38
Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey 38
Severe Inflammatory Bowel Disease Flares and COVID-19: Expand the Gastroenterology–Surgery Team to Include an Infectious Disease Specialist 37
Improvement in appropriateness and diagnostic yield of fast-track endoscopy during the COVID-19 pandemic in Northern Italy 35
Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy 35
Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds 34
Management of Post-Operative Crohn’s Disease: Knowns and Unknowns 34
Ulcerative colitis: Not only gut 34
Collecting and Analyzing IBD Clinical Data for Machine-Learning: Insights from an Italian Cohort 32
Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies 31
Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population 30
Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study 28
Inflammatory bowel disease in a colorectal cancer screening population: Diagnosis and follow-up 28
Proposal for returning to routine endoscopy during the COVID-19 pandemic: what is really feasible? 26
Upadacitinib in Patients With Difficult-to-Treat Crohn’s Disease 23
A multicenter study on bowel preparation in inflammatory bowel disease patients: comparison between 1L-PEG-ASC and 2L-PEG regimens in an outpatient setting 19
Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey 18
Building a Robust Investigator-Initiated Platform: The I-CARE Experience 17
Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions 15
Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence 15
What’s new in IBD research? Refining the agenda: Outcomes, patient-centered care, and technology 14
Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis 14
Sessile Serrated Lesions in Inflammatory Bowel Disease: Hidden Players in Colitis-Associated Colorectal Cancer? 13
Clinical phenotypes and therapeutic outcomes in enteropathic arthritis: a multivariate analysis from a retrospective cohort 13
Navigating Neoplasm Risk in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis 12
Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study 12
The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study 12
Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study 12
Upper Gastrointestinal Crohn’s Disease: Shedding Light on the Obscure L4 Classification Meaning 10
Drug Development in Inflammatory Bowel Diseases: What Is Next? 10
Digital biomarkers and artificial intelligence: a new frontier in personalized management of inflammatory bowel disease 10
How comparative studies can inform treatment decisions for Crohn’s disease 10
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study 9
Ulcerative colitis: current pharmacotherapy and future directions 9
Risk Factors for Inadequate Bowel Preparation Before Colonoscopy in Patients with Ulcerative Colitis in Clinical and Endoscopic Remission: A Multicenter Retrospective Cohort Study 9
Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis 9
Learning Curve in Intestinal Ultrasound: Advancing from Basic Skills to Advanced Competencies–Insights from the IUS IG-IBD Master Program 9
The impact of symptoms, irritable bowel syndrome pattern and diagnostic investigations on the diagnostic delay of Crohn's disease: A prospective study 9
Insights into the role of gastrointestinal ultrasound in ulcerative colitis 8
Aspecific ileitis: Crohn’s disease or not Crohn’s disease? A prospective study 8
Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study 8
Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease 8
Pre-illness changes in dietary habits and diet as a risk factor for inflammatory bowel disease: A case-control study 8
Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations 8
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC) 8
Prevalence of Disease-Related Malnutrition and Micronutrients Deficit in Patients with Inflammatory Bowel Disease: A Multicentric Cross-Sectional Study by the GSMII (Inflammatory Bowel Disease Study Group) 7
Upadacitinib is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-severe Ulcerative Colitis 7
Abdominal pain after minor trauma in a patient with Crohn's disease 7
New Technologies for IBD Endoscopy 7
Protein-losing enteropathy in inflammatory bowel diseases 7
Revolutionizing Crohn's disease monitoring: The emerging role of intestinal ultrasound 7
A safety evaluation of budesonide MMX for the treatment of ulcerative colitis 7
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation 7
Totale 3.418
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.277
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.277
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202210 0 0 0 3 0 0 0 1 1 0 4 1
2022/2023138 21 2 11 20 11 16 0 13 21 13 8 2
2023/2024184 3 11 23 6 2 8 8 4 0 39 34 46
2024/2025729 7 7 20 17 6 47 47 70 130 169 102 107
2025/20262.003 228 95 71 158 118 120 464 92 135 135 197 190
2026/2027503 273 230 0 0 0 0 0 0 0 0 0 0
Totale 3.581